HC Wainwright Comments on Delcath Systems Q1 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Delcath Systems in a research note issued on Friday, August 7th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2027 earnings at $0.12 EPS, Q3 2027 earnings at $0.00 EPS and Q4 2027 earnings at $0.02 EPS.

Several other research analysts have also commented on DCTH. Zacks Research raised Delcath Systems from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday. BTIG Research lifted their target price on Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.17.

Delcath Systems Trading Up 3.3%

Shares of NASDAQ DCTH opened at $17.22 on Monday. The stock has a market capitalization of $597.53 million, a PE ratio of 1,723.72 and a beta of 0.52. The stock’s fifty day simple moving average is $12.61 and its two-hundred day simple moving average is $10.97. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $17.42.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. The company had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royce & Associates LP purchased a new stake in Delcath Systems in the fourth quarter valued at about $1,566,000. Private Wealth Advisors LLC grew its stake in shares of Delcath Systems by 85.9% during the fourth quarter. Private Wealth Advisors LLC now owns 290,481 shares of the company’s stock worth $2,934,000 after acquiring an additional 134,198 shares during the last quarter. Leonteq Securities AG acquired a new position in shares of Delcath Systems during the fourth quarter valued at about $293,000. SkyOak Wealth LLC acquired a new position in shares of Delcath Systems during the fourth quarter valued at about $152,000. Finally, State of Alaska Department of Revenue raised its position in shares of Delcath Systems by 1,194.5% in the 4th quarter. State of Alaska Department of Revenue now owns 26,033 shares of the company’s stock valued at $262,000 after purchasing an additional 24,022 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.